Get the Stockscreener App
26.90
1.61%
-0.4459
Roivant Sciences Ltd stock is traded at $26.90, with a volume of 3.91M.
It is down -1.61% in the last 24 hours and up +22.43% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$27.35
Open:
$27.6
24h Volume:
3.91M
Relative Volume:
0.53
Market Cap:
$19.26B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
4.7618
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+24.30%
1M Performance:
+22.43%
6M Performance:
+140.91%
1Y Performance:
+156.53%
1-Day Range:
$26.30
$27.75
1-Week Range:
$20.99
$27.94
52-Week Range:
$8.73
$27.94
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
26.91 | 19.57B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.46 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.81 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
832.27 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.00 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.04 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV)Here's Why - Finviz
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright - Investing.com India
Citi raises Roivant Sciences stock price target to $35 from $26 By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs - Investing.com India
Citi raises Roivant Sciences stock price target to $35 from $26 - Investing.com India
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why - Insider Monkey
Roivant Sciences Earnings Call Highlights Brepocitinib Surge - TipRanks
Roivant Sciences stock hits all-time high at 26.35 USD By Investing.com - Investing.com Nigeria
Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings) - Benzinga
Roivant Sciences stock hits all-time high at 26.35 USD - Investing.com
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum - Yahoo Finance
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts - Yahoo Finance
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next - TechStock²
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?Lumentum Holdings (NASDAQ:LITE), Oshkosh (NYSE:OSK), Roivant Sciences (NASDAQ:ROIV), Regal Rexnord (N - Benzinga
Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund - MarketBeat
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Nigeria
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year HighStill a Buy? - MarketBeat
Roivant Sciences Q3 Earnings Call Highlights - MarketBeat
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c - StreetInsider
Roivant Sciences Swings to Fiscal Q3 Loss as Revenue Falls - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss - marketscreener.com
Roivant Sciences Ltd. Reports Positive Phase 2 Results and Financial Performance for Q3 2025 - TradingView
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Priovant pill sharply improves disfiguring skin sarcoidosis in Phase 2 - Stock Titan
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Jan 12 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,854,597 |
| Venker Eric | President & Immunovant CEO |
Jan 12 '26 |
Sale |
21.92 |
200,000 |
4,384,000 |
1,654,597 |
0.66%
2.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):